Zealand Pharma A/S (OTCMKTS:ZLDPF) Shares Gap Up – Time to Buy?

Zealand Pharma A/S (OTCMKTS:ZLDPF) gapped up prior to trading on Wednesday . The stock had previously closed at $38.95, but opened at $43.66. Zealand Pharma A/S shares last traded at $43.66, with a volume of 175 shares traded.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on ZLDPF shares. BNP Paribas Exane lowered shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research note on Friday, March 6th. William Blair reissued a “market perform” rating on shares of Zealand Pharma A/S in a research note on Friday, March 6th. Cantor Fitzgerald restated a “neutral” rating on shares of Zealand Pharma A/S in a report on Friday, March 6th. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating on shares of Zealand Pharma A/S in a research report on Thursday, June 4th. Three investment analysts have rated the stock with a Strong Buy rating and five have given a Hold rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy”.

Zealand Pharma A/S Price Performance

The firm has a market cap of $3.20 billion, a PE ratio of 3.32 and a beta of 0.86. The company has a debt-to-equity ratio of 0.02, a current ratio of 37.17 and a quick ratio of 37.17. The firm has a 50-day simple moving average of $47.92 and a 200 day simple moving average of $58.30.

Zealand Pharma A/S (OTCMKTS:ZLDPF) last released its earnings results on Thursday, May 7th. The company reported ($0.87) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.37) by $0.50. Zealand Pharma A/S had a net margin of 68.82% and a return on equity of 41.80%. The firm had revenue of $5.33 million for the quarter, compared to the consensus estimate of $2.81 million. As a group, equities analysts expect that Zealand Pharma A/S will post 2.37 EPS for the current year.

Zealand Pharma A/S Company Profile

Zealand Pharma A/S is a Denmark‐based biopharmaceutical company specializing in the discovery, design and development of peptide‐based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited.

Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia.